Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec 12;15(12):2763.
doi: 10.3390/pharmaceutics15122763.

Colorectal Cancer Stem Cells and Targeted Agents

Haobin Zhao  1   2 , Ruining Han  3 , Zhankun Wang  4 , Junfang Xian  1 , Xiaosu Bai  2
Affiliations
Review

Colorectal Cancer Stem Cells and Targeted Agents

Haobin Zhao et al. Pharmaceutics. .

Abstract

Since their discovery, cancer stem cells have become a hot topic in cancer therapy research. These cells possess stem cell-like self-renewal and differentiation capacities and are important factors that dominate cancer metastasis, therapy-resistance and recurrence. Worse, their inherent characteristics make them difficult to eliminate. Colorectal cancer is the third-most common cancer and the second leading cause of cancer death worldwide. Targeting colorectal cancer stem cells (CR-CSCs) can inhibit colorectal cancer metastasis, enhance therapeutic efficacy and reduce recurrence. Here, we introduced the origin, biomarker proteins, identification, cultivation and research techniques of CR-CSCs, and we summarized the signaling pathways that regulate the stemness of CR-CSCs, such as Wnt, JAK/STAT3, Notch and Hh signaling pathway. In addition to these, we also reviewed recent anti-CR-CSC drugs targeting signaling pathways, biomarkers and other regulators. These will help researchers gain insight into the current agents targeting to CR-CSCs, explore new cancer drugs and propose potential therapies.

Keywords: Lgr5; Wnt signaling pathway; colorectal cancer stem cells; single-cell omics technology.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Illustration of metastasis, therapy resistance and recurrence promoted by CR-CSCs.
Figure 2
Figure 2
Biomarker proteins and regulators in pathways in CR-CSCs.
See this image and copyright information in PMC

References

    1. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., Minden M., Paterson B., Caligiuri M.A., Dick J.E. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645–648. doi: 10.1038/367645a0. - DOI - PubMed
    1. Dontu G., Al-Hajj M., Abdallah W.M., Clarke M.F., Wicha M.S. Stem cells in normal breast development and breast cancer. Cell Prolif. 2003;36((Suppl. 1)):59–72. doi: 10.1046/j.1365-2184.36.s.1.6.x. - DOI - PMC - PubMed
    1. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., Dirks P.B. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63:5821–5828. - PubMed
    1. Maitland N.J., Collins A. A tumour stem cell hypothesis for the origins of prostate cancer. BJU Int. 2005;96:1219–1223. doi: 10.1111/j.1464-410X.2005.05744.x. - DOI - PubMed
    1. Lam J.S., Yamashiro J., Shintaku I.P., Vessella R.L., Jenkins R.B., Horvath S., Said J.W., Reiter R.E. Prostate stem cell antigen is overexpressed in prostate cancer metastases. Clin. Cancer Res. 2005;11:2591–2596. doi: 10.1158/1078-0432.CCR-04-1842. - DOI - PubMed

LinkOut - more resources